Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Weighted Kaplan-Meier estimators motivating to estimate HIV-1 RNA reduction censored by a limit of detection.

Ahmed I, Flandre P.

Stat Med. 2020 Mar 30;39(7):968-983. doi: 10.1002/sim.8455. Epub 2020 Jan 24.

PMID:
31981243
2.

HIV MDR is still a relevant issue despite its dramatic drop over the years.

Armenia D, Di Carlo D, Flandre P, Bouba Y, Borghi V, Forbici F, Bertoli A, Gori C, Fabeni L, Gennari W, Pinnetti C, Mondi A, Cicalini S, Gagliardini R, Vergori A, Bellagamba R, Malagnino V, Montella F, Colafigli M, Latini A, Marocco R, Licthner M, Andreoni M, Mussini C, Ceccherini-Silberstein F, Antinori A, Perno CF, Santoro MM.

J Antimicrob Chemother. 2020 Jan 24. pii: dkz554. doi: 10.1093/jac/dkz554. [Epub ahead of print]

PMID:
31976521
3.

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.

Abulizi X, Ribaudo HJ, Flandre P.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):44-51. doi: 10.1097/QAI.0000000000001978.

PMID:
30789450
4.

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.

Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P; ANRS AC43 Resistance Group.

J Antimicrob Chemother. 2019 May 1;74(5):1368-1375. doi: 10.1093/jac/dkz021.

PMID:
30789205
5.

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants.

Delagreverie HM, Grude M, Lambert-Niclot S, Nere ML, Jadand C, Leport C, Raffi F, Ghislain M, Goujard C, Meyer L, Calvez V, Katlama C, Flandre P, Barin F, Delaugerre C.

J Antimicrob Chemother. 2019 May 1;74(5):1389-1394. doi: 10.1093/jac/dkz004.

PMID:
30690509
6.
7.

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.

Nguyen T, Fofana DB, Lê MP, Charpentier C, Peytavin G, Wirden M, Lambert-Niclot S, Desire N, Grude M, Morand-Joubert L, Flandre P, Katlama C, Descamps D, Calvez V, Todesco E, Marcelin AG.

J Antimicrob Chemother. 2018 Sep 1;73(9):2485-2492. doi: 10.1093/jac/dky198.

PMID:
29873733
8.

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.

Lambert-Niclot S, Grude M, Meynard JL, Marcelin AG, Valantin MA, Flandre P, Izopet J, Moinot L, Bouteloup V, Calvez V, Katlama C, Girard PM, Morand-Joubert L.

Clin Infect Dis. 2018 Nov 28;67(12):1883-1889. doi: 10.1093/cid/ciy382.

9.

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).

Lambert-Niclot S, Grude M, Chaix ML, Charpentier C, Reigadas S, Le Guillou-Guillemette H, Rodallec A, Amiel C, Maillard A, Dufayard J, Mourez T, Mirand A, Guinard J, Montes B, Vallet S, Marcelin AG, Descamps D, Flandre P, Delaugerre C, Morand-Joubert L; ANRS AC-11 Resistance Group.

J Antimicrob Chemother. 2018 Aug 1;73(8):2147-2151. doi: 10.1093/jac/dky142.

PMID:
29718247
10.
11.

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study.

Cuzin L, Pugliese P, Allavena C, Rey D, Chirouze C, Bani-Sadr F, Cabié A, Huleux T, Poizot-Martin I, Cotte L, Isnard Bagnis C, Flandre P; Dat’AIDS study group.

PLoS One. 2017 Dec 7;12(12):e0187517. doi: 10.1371/journal.pone.0187517. eCollection 2017.

12.

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.

Flandre P, Marcelin AG, Calvez V; ANRS AC11 Resistance Study Group.

J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):448-454. doi: 10.1097/QAI.0000000000001435.

PMID:
28653971
13.

Accuracy of predictive ability measures for survival models.

Flandre P, Deutsch R, O'Quigley J.

Stat Med. 2017 Sep 10;36(20):3171-3180. doi: 10.1002/sim.7342. Epub 2017 Jun 7.

PMID:
28589544
14.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.

Soulie C, Grudé M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferré V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2351-2354. doi: 10.1093/jac/dkx128.

PMID:
28472307
15.

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.

Lambert-Niclot S, Allavena C, Grude M, Flandre P, Sayon S, Andre E, Wirden M, Rodallec A, Jovelin T, Katlama C, Calvez V, Raffi F, Marcelin AG.

J Antimicrob Chemother. 2016 Aug;71(8):2248-51. doi: 10.1093/jac/dkw146. Epub 2016 May 26.

PMID:
27231280
16.

Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.

Flandre P, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Cuzin L; Dat'AIDS Study group.

HIV Med. 2016 May;17(5):380-4. doi: 10.1111/hiv.12306. Epub 2015 Aug 26.

17.

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

Flandre P, Pugliese P, Allavena C, Isnard Bagnis C, Cuzin L; Dat’AIDS study Group.

AIDS. 2016 Jun 1;30(9):1433-8. doi: 10.1097/QAD.0000000000001065.

PMID:
26891036
18.

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Günthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schülter E, Torti C, van Sighem A, Zangerle R, Descamps D; CHAIN and COHERE in EuroCoord.

J Antimicrob Chemother. 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465. Epub 2016 Jan 28.

19.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

20.

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach.

Cuzin L, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Flandre P; Dat'AIDS Study group.

Medicine (Baltimore). 2015 Sep;94(39):e1668. doi: 10.1097/MD.0000000000001668.

21.

Choice of effect measure in HIV randomized trials.

Flandre P.

AIDS. 2015 Sep 24;29(15):2057-60. doi: 10.1097/QAD.0000000000000820.

PMID:
26355576
22.

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.

Rodriguez C, Soulié C, Marcelin AG, Calvez V, Descamps D, Charpentier C, Flandre P, Recordon-Pinson P, Bellecave P, Pawlotsky JM, Masquelier B; ANRS AC11 Study Group.

PLoS One. 2015 Jun 11;10(6):e0127816. doi: 10.1371/journal.pone.0127816. eCollection 2015.

23.

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.

Vingerhoets J, Calvez V, Flandre P, Marcelin AG, Ceccherini-Silberstein F, Perno CF, Mercedes Santoro M, Bateson R, Nelson M, Cozzi-Lepri A, Grarup J, Lundgren J, Incardona F, Kaiser R, Sonnerborg A, Clotet B, Paredes R, Günthard HF, Ledergerber B, Hoogstoel A, Nijs S, Tambuyzer L, Lavreys L, Opsomer M; Etravirine Cohort Study Group.

HIV Med. 2015 May;16(5):297-306. doi: 10.1111/hiv.12218. Epub 2015 Jan 14.

24.

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.

Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2015 May;70(5):1507-12. doi: 10.1093/jac/dku535. Epub 2015 Jan 3.

PMID:
25558077
25.

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

Soulie C, Descamps D, Grudé M, Schneider V, Trabaud MA, Morand-Joubert L, Delaugerre C, Montes B, Barin F, Ferre V, Raymond S, Jeulin H, Alloui C, Yerly S, Pallier C, Reigadas S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS Resistance AC11 Group.

J Antimicrob Chemother. 2015 Feb;70(2):566-72. doi: 10.1093/jac/dku419. Epub 2014 Oct 25.

PMID:
25344810
26.

Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.

Gallien S, Flandre P, Nguyen N, De Castro N, Molina JM, Delaugerre C.

J Med Virol. 2015 Feb;87(2):187-91. doi: 10.1002/jmv.24023. Epub 2014 Jul 28.

PMID:
25070158
27.

Some current issues in the design of HIV noninferiority trials.

Flandre P.

AIDS. 2014 Aug 24;28(13):1921-9. doi: 10.1097/QAD.0000000000000369.

PMID:
24945620
28.

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.

Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG.

J Antimicrob Chemother. 2014 Apr;69(4):1086-9. doi: 10.1093/jac/dkt463. Epub 2013 Dec 2.

PMID:
24302653
29.

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.

Fourati S, Flandre P, Calin R, Carcelain G, Soulie C, Lambert-Niclot S, Maiga A, Ait-Arkoub Z, Tubiana R, Valantin MA, Autran B, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2014 Mar;69(3):753-6. doi: 10.1093/jac/dkt428. Epub 2013 Nov 1.

PMID:
24187041
30.

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity.

Wright DW, Deuzing IP, Flandre P, van den Eede P, Govaert M, Setiawan L, Coveney PV, Marcelin AG, Calvez V, Boucher CA, Beerens N.

PLoS One. 2013 Oct 2;8(10):e74078. doi: 10.1371/journal.pone.0074078. eCollection 2013.

31.

Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals.

Psomas C, Lavigne JP, Barbuat C, Trabelsi S, Ghosn J, Lascoux-Combe C, Flandre P, Cuzin L, Reynes J, Autran B, Corbeau P.

Blood. 2013 Sep 26;122(13):2282-3. doi: 10.1182/blood-2013-06-507012. No abstract available.

PMID:
24072848
32.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group.

Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4.

PMID:
23562640
33.

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set.

Houssaini A, Assoumou L, Miller V, Calvez V, Marcelin AG, Flandre P.

PLoS One. 2013;8(3):e59014. doi: 10.1371/journal.pone.0059014. Epub 2013 Mar 21.

34.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG.

J Antimicrob Chemother. 2013 Jun;68(6):1237-42. doi: 10.1093/jac/dkt003. Epub 2013 Jan 29.

PMID:
23361642
35.

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.

Charpentier C, Lambert-Niclot S, Alteri C, Storto A, Flandre P, Svicher V, Perno CF, Brun-Vézinet F, Calvez V, Marcelin AG, Ceccherini-Silberstein F, Descamps D.

PLoS One. 2013;8(1):e54381. doi: 10.1371/journal.pone.0054381. Epub 2013 Jan 18.

36.

Impact of pre-therapy viral load on virological response to modern first-line HAART.

Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF.

Antivir Ther. 2013;18(7):867-76. doi: 10.3851/IMP2531. Epub 2013 Jan 23.

PMID:
23343501
37.

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.

Reigadas S, Marcelin AG, Houssaïni A, Yerly S, Descamps D, Plantier JC, Ruffault A, Amiel C, Trabaud MA, Flandre P, Fleury H, Masquelier B; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2013 Apr;68(4):969-72. doi: 10.1093/jac/dks474. Epub 2012 Nov 25. No abstract available.

PMID:
23184711
38.

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.

Soulié C, Charpentier C, Flandre P, Nino C, Carcelain G, Simon A, Katlama C, Landman R, Brun-Vézinet F, Descamps D, Calvez V, Marcelin AG.

J Med Virol. 2012 Dec;84(12):1853-6. doi: 10.1002/jmv.23362.

PMID:
23080487
39.

Design of HIV noninferiority trials: where are we going?

Flandre P.

AIDS. 2013 Feb 20;27(4):653-7. doi: 10.1097/QAD.0b013e32835b105e.

PMID:
23079799
40.

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.

Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L, Fourn E, Duvivier C, Simon A, Courbon E, Murphy R, Flandre P, Peytavin G, Katlama C; RADAR Study Group.

J Med Virol. 2013 Jan;85(1):8-15. doi: 10.1002/jmv.23404. Epub 2012 Sep 28.

PMID:
23024008
41.

Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.

Cuzin L, Trabelsi S, Delobel P, Barbuat C, Reynes J, Allavena C, Peytavin G, Ghosn J, Lascoux-Combe C, Psomas C, Corbeau P, Flandre P; ANRS 145 MARIMUNO Study group.

J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):557-64. doi: 10.1097/QAI.0b013e318273015f.

PMID:
22986949
42.

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.

Lambert-Niclot S, Flandre P, Valantin MA, Soulie C, Fourati S, Wirden M, Sayon S, Pakianather S, Bocket L, Masquelier B, Dos Santos G, Katlama C, Calvez V, Marcelin AG.

PLoS One. 2012;7(7):e41390. doi: 10.1371/journal.pone.0041390. Epub 2012 Jul 25.

43.

Risk factors for raltegravir resistance development in clinical practice.

Malet I, Fourati S, Morand-Joubert L, Flandre P, Wirden M, Haim-Boukobza S, Sayon S, Pattery T, Simon A, Katlama C, Girard PM, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2012 Oct;67(10):2494-500. doi: 10.1093/jac/dks254. Epub 2012 Jul 4.

PMID:
22763565
44.

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.

Fourati S, Malet I, Lambert S, Soulie C, Wirden M, Flandre P, Fofana DB, Sayon S, Simon A, Katlama C, Calvez V, Marcelin AG.

AIDS. 2012 Aug 24;26(13):1619-24. doi: 10.1097/QAD.0b013e3283560703.

PMID:
22695298
45.

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, Timsit J, Molina JM, de Truchis P.

PLoS One. 2012;7(5):e36673. doi: 10.1371/journal.pone.0036673. Epub 2012 May 10.

46.

Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data.

Houssaïni A, Assoumou L, Marcelin AG, Molina JM, Calvez V, Flandre P.

AIDS Res Treat. 2012;2012:478467. doi: 10.1155/2012/478467. Epub 2012 Apr 3.

47.

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

Santoro MM, Alteri C, Ronga L, Flandre P, Fabeni L, Mercurio F, D'Arrigo R, Gori C, Palamara G, Bertoli A, Forbici F, Salpini R, Boumis E, Tozzi V, Visco-Comandini U, Zaccarelli M, Van Houtte M, Pattery T, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1285-93. Epub 2012 Apr 18.

48.

Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.

Valantin MA, Kolta S, Flandre P, Algarte Genin M, Meynard JL, Ponscarme D, Slama L, Cuzin L, de Kerviler E, Inaoui R, Katlama C.

HIV Med. 2012 Sep;13(8):505-15. doi: 10.1111/j.1468-1293.2012.01004.x. Epub 2012 Mar 14.

49.

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.

Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Sayon S, Morand-Joubert L, Delaugerre C, Algarte-Genin M, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2012 Jun;67(6):1470-4. doi: 10.1093/jac/dks052. Epub 2012 Mar 5.

PMID:
22396434
50.

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey.

Lambert-Niclot S, Tubiana R, Beaudoux C, Lefebvre G, Caby F, Bonmarchand M, Naouri M, Schubert B, Dommergues M, Calvez V, Flandre P, Poirot C, Marcelin AG.

AIDS. 2012 May 15;26(8):971-5. doi: 10.1097/QAD.0b013e328352ae09.

PMID:
22382146

Supplemental Content

Loading ...
Support Center